Intrexon | XON - Loan Capital


Intrexon reported $0 in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
Agenus USD 169.66M 146.06M Dec/2025
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 538.1M 323.22M Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Gilead Sciences USD 22.13B 6M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 29.41M 785K Mar/2026
Intrexon USD 0 198.67M Jun/2024
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
MacroGenics USD 70M 256K Dec/2025
MannKind USD 548.44M 244.79M Dec/2025
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 40.07B 4.22B Mar/2026
Veracyte USD 0 0 Mar/2025
Xencor USD 76.48M 11.29M Dec/2025